Clinical Trial Update: To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1 [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating the safety and tolerability of sublingual lobeline at 7.5, 15, and 30 mg in individuals with amphetamine-related disorders.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amphetamine Use Disorder
• Stimulant Use Disorder

Drugs mentioned

• Lobeline (lobeline)

Snippet

Sponsor: National Institute on Drug Abuse (NIDA) | Conditions: Amphetamine-Related Disorders | Phase 1 | Status: UNKNOWN